SECURITIES AND EXCHANGE

COMMISSION

  Washington, D.C. 20549  

 

 

 

SCHEDULE 13G/A

 

(Rule 13d-102)

 

(Amendment No. 1)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT 

TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO 

FILED PURSUANT TO RULE 13d-2

 

NPS Pharmaceuticals, Inc. 

(Name of Issuer)

 

Common Stock 

(Title of Class of Securities)

 

62936P103 

(CUSIP Number)

 

December 31, 2014 

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 
 


CUSIP No. 62936P103
 
  1.

Name of Reporting Person.
I.R.S. Identification No. of Above Person (Entities Only).

 

ING Groep N.V.

 

 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) o
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
The Netherlands
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:
5. Sole Voting Power
0
 
6. Shared Voting Power
0
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
0
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
0
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
0%
 
  12. Type of Reporting Person (See Instructions)
HC
           
2
 
CUSIP No. 62936P103
 
  1.

Name of Reporting Person.
I.R.S. Identification No. of Above Person (Entities Only).

 

ING Bank N.V.

 

 
  2. Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) o
    (b) o
 
  3. SEC Use Only
 
  4. Citizenship or Place of Organization
The Netherlands
     
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:
5. Sole Voting Power
0
 
6. Shared Voting Power
0
 
7. Sole Dispositive Power
0
 
8. Shared Dispositive Power
0
 
  9. Aggregate Amount Beneficially Owned by Each Reporting Person
0
 
  10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
 
  11. Percent of Class Represented by Amount in Row (9)
0
 
  12. Type of Reporting Person (See Instructions)
CO
           
3
 
Item 1(a).

Name of Issuer:

 

NPS Pharmaceuticals, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:

 

550 Hills Drive 

Bedminster, NJ 07921 

United States of America 

 
Item 2(a).

Name of Person Filing:

 

ING Groep N.V. 

ING Bank N.V. 

Item 2(b).

Address of Principal Business Office or, if none, Residence:

 

ING Groep N.V. 

Bijlmerplein 888 

1102 MG 

Amsterdam-Zuidoost 

Postbus 1800 

1000 BV Amsterdam 

The Netherlands

 

ING Bank N.V. 

Bijlmerplein 888 

1102 MG 

Amsterdam-Zuidoost 

Postbus 1800
1000 BV Amsterdam
The Netherlands 

Item 2(c).

Citizenship:

 

ING Groep N.V. – The Netherlands 

ING Bank N.V. – The Netherlands 

Item 2(d).

Title of Class of Securities:

 

Common Stock 

Item 2(e).

CUSIP Number:

 

62936P103 

 
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), 13d-2(b) or (c), Check Whether the Person Filing is a:
  (a) o Broker or dealer registered under Section 15 of the Exchange Act.
  (b) o Bank as defined in Section 3(a)(6) of the Exchange Act.
  (c) o Insurance company as defined in Section 3(a)(19) of the Exchange Act.
  (d) o Investment company as defined under Section 8 of the Investment Company Act.
  (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
  (f) o An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
  (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
  (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
  (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
  (j) o Group, in accordance with §240.13d-1(b)(1)(ii)(J).
  Not Applicable.
4
 
Item 4. Ownership:
  (a) Not Applicable.
  (b) Not Applicable.
  (c) Not Applicable.
 
Item 5. Ownership of Five Percent or Less of a Class:
  X
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
  Not Applicable.
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
  Not Applicable.
 
Item 8. Identification and Classification of Members of the Group.
  Not Applicable.
 
Item 9. Notice of Dissolution of Group.
  Not Applicable.
   
Item 10. Certification.
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

5
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated:  February 11, 2015

 

  ING GROEP N.V.
     
  By: /s/ J.A.M. Emke-Petrelluzzi Bojanic
  (Signature)
   
   
  J.A.M. Emke-Petrelluzzi Bojanic
  Senior Compliance Officer (Name/Title)
   
   
  By: /s/ Fred Severin
  (Signature)
   
   
  Fred Severin
  Compliance Officer (Name/Title)
   
   
   
  ING BANK N.V.
   
   
  By:   /s/ J.A.M. Emke-Petrelluzzi Bojanic
  (Signature)
   
   
  J.A.M. Emke-Petrelluzzi Bojanic
  Senior Compliance Officer (Name/Title)
   
     
  By: /s/ Fred Severin
  (Signature)
   
   
  Fred Severin
  Compliance Officer (Name/Title)
6
 

Exhibit A to Schedule 13G 

Joint Filing Agreement 

Pursuant to Rule 13d-1(k)

 

The undersigned persons (the “Reporting Persons”) hereby agree that a joint statement on this Schedule 13G, and any amendments thereto, be filed on their behalf by ING Groep N.V.

 

Each of the Reporting Persons is responsible for the completeness and accuracy of the information concerning each of them contained therein, but none of the Reporting Persons is responsible for the completeness or accuracy of the information concerning any other Reporting Person.

 

Dated:  February 11, 2015

 

  ING GROEP N.V.
     
  By: /s/ J.A.M. Emke-Petrelluzzi Bojanic
  (Signature)
   
   
  J.A.M. Emke-Petrelluzzi Bojanic
  Senior Compliance Officer (Name/Title)
   
     
  By: /s/ Fred Severin
  (Signature)
   
   
  Fred Severin
  Compliance Officer (Name/Title)
   
   
   
  ING BANK N.V.
     
  By: /s/ J.A.M. Emke-Petrelluzzi Bojanic
  (Signature)
   
   
  J.A.M. Emke-Petrelluzzi Bojanic
  Senior Compliance Officer (Name/Title)
   
     
  By: /s/ Fred Severin
  (Signature)
   
   
  Fred Severin
  Compliance Officer (Name/Title)
7